Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

4 results about "Neuron cell death" patented technology

Via the process of apoptosis, otherwise known as programmed cell death once a cell is no longer efficient. NEURONAL CELL DEATH: "There is a wide range of possibilities for which could explain neuronal cell death from apoptosis to lack of nutrients.".

Inhibitors of short-chain dehydrogenase activity for promoting neurogenesis and inhibiting nerve cell death

PendingUS20260007642A1Organic active ingredientsNervous disorderNeuron cell deathDisease
A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and / or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and / or treating a disease, disorder, and / or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.
Owner:CASE WESTERN RESERVE UNIV +3

Novel irisin peptides and methods of use thereof

The present invention provides novel irisin peptides (e.g, irisin glycosylation mutants and biologically active fragments thereof). Also provided are methods for preventing or reducing degeneration of dopaminergic neurons and / or preventing or ameliorating at least one motor deficit in a subject in need thereof, such as in a subject with α-synucleinopathy, using the novel irisin peptides to modulate irisin-induced integrin signaling. The novel irisin peptides can also be used in methods for increasing expression of brain-derived neurotrophic factor (BDNF), and / or treating or preventing neurological diseases or disorders that would benefit from decreased neuronal cell death and / or increased neuronal survival in a subject. In addition, the novel irisin peptides may be used in methods for preventing or treating muscular atrophy or muscular dystrophy.
Owner:DANA FARBER CANCER INSTITUTE INC

Calpain-2 inhibitor compounds and methods of treatment

ActiveUS12606520B2Organic chemistrySolution deliveryNeuron cell deathCalpactins
Compounds of Formula (I) or (X) are provided including for treatment of disorders such as a disorder or symptom associated with neuronal cell death. In one aspect, compounds which are selective inhibitors of calpain-2 are provided. Preferred compounds can be useful to treat acute neurodegeneration.
Owner:WESTERN UNIV OF HEALTH SCI

Methods and Dosing Regimens for Preventing or Delaying Onset of Alzheimer's Disease and Other Forms of Dementia and Mild Cognitive Impairment

PendingUS20260126455A1Nervous disorderDisease diagnosisDosing regimenNeuron cell death
Methods and dosing regimens using alpha 7 acetylcholine nicotine receptor binding agents are provided to prevent or inhibit intracellular accumulation of amyloid in cells leading to inhibition or prevention of neuronal cell death. In addition, these methods and dosing regimens are coupled with methods and dosing regimens to reduce and / or prevent blood-brain barrier leakage of vascular-derived amyloid into the brain and / or methods and dosing regimens to reduce and / or prevent neuroinflammation to prevent and / or inhibit the progression of Alzheimer's disease and other forms of dementia and mild cognitive impairment. Also provided are methods for identifying individuals for this treatment.
Owner:ZACHRIEL NEUROSCIENCES LLC